Deutsche Bank Ag\ Adaptive Biotechnologies Corp Transaction History

Deutsche Bank Ag\

$287 Billion
Q3 2025

A detailed history of Deutsche Bank Ag\ transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Deutsche Bank Ag\ holds 1,713,139 shares of ADPT stock, worth $24.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,713,139

Previous 170,454 905.04%

Holding current value

$24.2 Million

Previous $1.99 Million 1191.08%

% of portfolio

0.01%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$10.24 - $14.96 $15.8 Million - $23.1 Million	1,542,685 Added 905.04%	1,713,139 $25.6 Million
Q2 2025 Aug 12, 2025	SELL	$6.83 - $12.16 $3.06 Million - $5.44 Million	-447,721 Reduced 72.43%	170,454 $1.99 Million
Q1 2025 May 09, 2025	SELL	$6.07 - $8.66 $75,280 - $107,401	-12,402 Reduced 1.97%	618,175 $4.59 Million
Q4 2024 Jun 30, 2025	BUY	$4.37 - $6.78 $54,196 - $84,085	12,402 Added 2.01%	630,577 $3.78 Million
Q4 2024 Feb 14, 2025	BUY	$4.37 - $6.78 $2.2 Million - $3.42 Million	503,842 Added 397.56%	630,577 $3.78 Million

Q3 2024 Jun 26, 2025	SELL	$3.37 - $5.12 $1.66 Million - $2.52 Million	-491,440 Reduced 79.5%	126,735 $648,000
Q3 2024 Nov 13, 2024	SELL	$3.37 - $5.12 $1.55 Million - $2.35 Million	-458,968 Reduced 78.36%	126,735 $648,000
Q2 2024 Jun 12, 2025	SELL	$2.34 - $3.96 $75,984 - $128,589	-32,472 Reduced 5.25%	585,703 $2.12 Million
Q2 2024 Aug 14, 2024	SELL	$2.34 - $3.96 $43,999 - $74,459	-18,803 Reduced 3.11%	585,703 $2.12 Million
Q1 2024 Jun 02, 2025	SELL	$2.88 - $4.8 $39,366 - $65,611	-13,669 Reduced 2.21%	604,506 $1.94 Million
Q1 2024 May 15, 2024	BUY	$2.88 - $4.8 $4,176 - $6,960	1,450 Added 0.24%	604,506 $1.94 Million
Q4 2023 Feb 14, 2024	BUY	$3.46 - $5.33 $1.89 Million - $2.91 Million	546,069 Added 958.23%	603,056 $2.95 Million
Q3 2023 Nov 09, 2023	SELL	$5.07 - $8.44 $2.74 Million - $4.56 Million	-540,190 Reduced 90.46%	56,987 $310,000
Q2 2023 Aug 14, 2023	SELL	$6.19 - $8.78 $234,514 - $332,639	-37,886 Reduced 5.97%	597,177 $4.01 Million
Q1 2023 May 15, 2023	BUY	$7.8 - $10.11 $96,291 - $124,807	12,345 Added 1.98%	635,063 $5.61 Million
Q4 2022 Feb 13, 2023	SELL	$6.26 - $9.34 $196,157 - $292,668	-31,335 Reduced 4.79%	622,718 $4.76 Million
Q3 2022 Nov 14, 2022	BUY	$6.5 - $12.67 $36,731 - $71,598	5,651 Added 0.87%	654,053 $4.66 Million
Q2 2022 Aug 11, 2022	BUY	$6.4 - $14.73 $1.96 Million - $4.52 Million	306,982 Added 89.91%	648,402 $5.25 Million
Q1 2022 May 13, 2022	BUY	$10.12 - $28.9 $2.09 Million - $5.97 Million	206,421 Added 152.91%	341,420 $4.74 Million
Q4 2021 Feb 11, 2022	SELL	$25.17 - $36.85 $554,042 - $811,142	-22,012 Reduced 14.02%	134,999 $3.79 Million
Q3 2021 Nov 04, 2021	BUY	$30.02 - $39.87 $327,878 - $435,460	10,922 Added 7.48%	157,011 $5.34 Million
Q2 2021 Aug 11, 2021	SELL	$32.22 - $44.59 $602,868 - $834,323	-18,711 Reduced 11.35%	146,089 $5.97 Million
Q1 2021 May 13, 2021	BUY	$37.26 - $67.74 $4.66 Million - $8.47 Million	125,067 Added 314.77%	164,800 $6.63 Million
Q4 2020 Feb 16, 2021	SELL	$45.01 - $65.47 $5.11 Million - $7.44 Million	-113,601 Reduced 74.09%	39,733 $2.35 Million
Q3 2020 Nov 12, 2020	BUY	$35.79 - $48.81 $3.84 Million - $5.24 Million	107,309 Added 233.15%	153,334 $7.46 Million
Q2 2020 Aug 13, 2020	SELL	$24.95 - $48.38 $8.97 Million - $17.4 Million	-359,678 Reduced 88.66%	46,025 $2.23 Million
Q1 2020 May 14, 2020	BUY	$16.96 - $34.16 $6.52 Million - $13.1 Million	384,326 Added 1797.85%	405,703 $11.3 Million
Q4 2019 Feb 14, 2020	BUY	$24.56 - $32.8 $337,700 - $450,999	13,750 Added 180.28%	21,377 $637,000
Q3 2019 Nov 14, 2019	BUY	$30.31 - $53.51 $231,174 - $408,120	7,627 New	7,627 $235,000

Others Institutions Holding ADPT

# of Institutions

289

Shares Held

147M

Call Options Held

23.5K

Put Options Held

33.3K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $2.01B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account